With 2.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.36 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.585 whereas the lowest price it dropped to was $2.375. The 52-week range on RLAY shows that it touched its highest point at $10.72 and its lowest point at $2.45 during that stretch. It currently has a 1-year price target of $19.90. Beta for the stock currently stands at 1.70.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RLAY was down-trending over the past week, with a drop of -16.55%, but this was down by -22.81% over a month. Three-month performance dropped to -43.35% while six-month performance fell -66.89%. The stock lost -70.24% in the past year, while it has lost -40.05% so far this year. A look at the trailing 12-month EPS for RLAY yields -2.40 with Next year EPS estimates of -2.34. For the next quarter, that number is -0.52. This implies an EPS growth rate of 6.14% for this year and -5.46% for next year. EPS is expected to grow by 0.41% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -23.05%.
Float and Shares Shorts:
At present, 167.76 million RLAY shares are outstanding with a float of 127.70 million shares on hand for trading. On 2025-03-14, short shares totaled 19.12 million, which was 1127.9999500000001 higher than short shares on 1739491200. In addition to Mr. Alexis A. Borisy A.M. as the firm’s Co-Founder & Independent Chairman, Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS serves as its CEO, President & Director.
Institutional Ownership:
Through their ownership of 1.04134 of RLAY’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, RLAY reported revenue of $0.0 and operating income of -$84979000.0. The EBITDA in the recently reported quarter was -$83645000.0 and diluted EPS was -$0.45.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RLAY since 8 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RLAY analysts setting a high price target of 30.0 and a low target of 12.0, the average target price over the next 12 months is 19.63636. Based on these targets, RLAY could surge 1114.57% to reach the target high and rise by 385.83% to reach the target low. Reaching the average price target will result in a growth of 694.99% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.28187 being high and -$2.7048 being low. For RLAY, this leads to a yearly average estimate of -$2.50809.
